|1.||Scott, Andrew M: 13 articles (05/2015 - 03/2002)|
|2.||Johns, Terrance G: 12 articles (10/2010 - 03/2002)|
|3.||Burgess, Antony W: 8 articles (06/2012 - 03/2002)|
|4.||Old, Lloyd J: 7 articles (12/2007 - 03/2002)|
|5.||Gan, Hui K: 5 articles (06/2012 - 09/2005)|
|6.||Jungbluth, Achim A: 5 articles (03/2007 - 03/2002)|
|7.||Smyth, Fiona E: 4 articles (10/2010 - 03/2002)|
|8.||Ritter, Gerd: 4 articles (03/2007 - 03/2002)|
|9.||Cavenee, Webster K: 3 articles (09/2009 - 03/2002)|
|10.||Perera, Rushika M: 3 articles (12/2007 - 12/2003)|
03/06/2007 - "The present clinical study was designed to examine the in vivo specificity of a chimeric form of mAb 806 (ch806) in a tumor targeting/biodistribution/pharmacokinetic analysis in patients with diverse tumor types. "
05/01/2015 - "MAb 806 is a novel EGFR antibody that selectively targets a tumor-selective epitope suggesting that a mAb 806-based therapeutic would retain antitumor activity without the on-target toxicities associated with EGFR inhibition. "
12/01/2007 - "We investigated the intracellular trafficking of fluorescently tagged mAb 806 in live cells and analyzed its biodistribution in a tumor xenografted nude mouse model. "
05/01/2005 - "These precursor forms of the EGFR thus represent novel tumor targets and contribute to the exceptional selectivity of mAb 806 for EGFR when overexpressed in cancer cells. "
03/20/2002 - "Thus, MAb 806 can be used to target tumor cells containing amplification of the EGFR gene or de2-7 EGFR but does not bind to the wild type EGFR when expressed on the cell surface."
07/15/2001 - "We tested the efficacy of a novel monoclonal anti-DeltaEGFR antibody, mAb 806, on the growth of intracranial xenografted gliomas in nude mice. "
03/20/2002 - "MAb 806 bound to de2-7 EGFR transfected U87MG glioma cells (U87MG.Delta 2-7) with high affinity (approximately 1 x 10(9) M(-1)), but did not bind parental cells that express the wild type EGFR. "
07/15/2001 - "These data provide preclinical evidence that mAb 806 treatment may be a useful biotherapeutic agent for those aggressive gliomas that express DeltaEGFR."
07/15/2001 - "A slight increase of survival of mice xenografted with a wild-type EGFR-overexpressing U87 MG glioma (U87 MG.wtEGFR) was effected by mAb 806 concordant with its weak cross-reactivity with such cells. "
10/01/2010 - "We have previously shown that mAb 806, a novel EGFR-specific antibody, is able to inhibit the growth of U87MG.Δ2-7 glioma xenografts expressing the de2-7 EGFR and may have potential as a therapeutic. "
|4.||Glioblastoma (Glioblastoma Multiforme)
|1.||Epidermal Growth Factor Receptor (EGF Receptor)
|2.||dasatinib (BMS 354825)
|3.||epidermal growth factor receptor VIII
|4.||tyrphostin AG 1478
|5.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|7.||Epidermal Growth Factor (EGF)
|1.||Heterologous Transplantation (Xenotransplantation)